(DHC) Diversified Healthcare Trust - Overview
Stock: Senior Living, Medical Office, Life Science
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.15% |
| Yield on Cost 5y | 0.97% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 88.7% |
| Payout Ratio | 2.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 38.7% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.80 |
| Alpha | 130.88 |
| Character TTM | |
|---|---|
| Beta | 0.787 |
| Beta Downside | 0.943 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.64% |
| CAGR/Max DD | 2.10 |
Description: DHC Diversified Healthcare Trust January 26, 2026
Diversified Healthcare Trust (NASDAQ:DHC) is a U.S. REIT that acquires and operates high-quality healthcare real estate, spanning senior living, medical office, and life-science facilities across 34 states and Washington, D.C.
As of September 30 2025 the portfolio was valued at roughly $6.7 billion and comprised 335 properties, including more than 26,000 senior-living units and about 6.9 million sq ft of medical-office and life-science space occupied by ~420 tenants. The REIT reported an occupancy rate of 96.2% in Q4 2025 and delivered a 5.1% year-over-year increase in funds-from-operations (FFO), reflecting strong demand for health-care space amid an aging U.S. population and historically low vacancy in the sector.
DHC is managed by The RMR Group (NASDAQ:RMR), a specialist alternative-asset manager with ~$39 billion AUM and more than three decades of experience in commercial-real-estate transactions. The firm’s capital structure remains conservative, with a net debt-to-EBITDA ratio of 3.2× at the end of 2025, providing flexibility to fund acquisitions or refinance in a rising-interest-rate environment.
For a deeper, data-driven view of DHC’s valuation relative to peers, you may find ValueRay’s analytics platform useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -352.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: 28.48% < 20% (prev 21.48%; Δ 7.00% < -1%) |
| CFO/TA 0.00 > 3% & CFO 18.7m > Net Income -352.1m |
| Net Debt (2.52b) to EBITDA (98.6m): 25.59 < 3 |
| Current Ratio: 15.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.4m) vs 12m ago 0.30% < -2% |
| Gross Margin: 17.57% > 18% (prev 0.17%; Δ 1740 % > 0.5%) |
| Asset Turnover: 30.85% > 50% (prev 27.95%; Δ 2.90% > 0%) |
| Interest Coverage Ratio: -0.82 > 6 (EBITDA TTM 98.6m / Interest Expense TTM 217.9m) |
Altman Z'' -2.70
| A: 0.09 (Total Current Assets 468.0m - Total Current Liabilities 30.0m) / Total Assets 4.68b |
| B: -0.63 (Retained Earnings -2.94b / Total Assets 4.68b) |
| C: -0.04 (EBIT TTM -179.0m / Avg Total Assets 4.98b) |
| D: -0.98 (Book Value of Equity -2.93b / Total Liabilities 3.00b) |
| Altman-Z'' Score: -2.70 = D |
What is the price of DHC shares?
Over the past week, the price has changed by +9.64%, over one month by +21.78%, over three months by +43.40% and over the past year by +137.77%.
Is DHC a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the DHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | -9.7% |
| Analysts Target Price | 5.8 | -9.7% |
| ValueRay Target Price | 7.5 | 17% |
DHC Fundamental Data Overview February 07, 2026
P/B = 0.8618
Revenue TTM = 1.54b USD
EBIT TTM = -179.0m USD
EBITDA TTM = 98.6m USD
Long Term Debt = 2.72b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.52b USD (from netDebt column, last quarter)
Enterprise Value = 4.02b USD (1.50b + Debt 2.72b - CCE 201.4m)
Interest Coverage Ratio = -0.82 (Ebit TTM -179.0m / Interest Expense TTM 217.9m)
EV/FCF = 215.3x (Enterprise Value 4.02b / FCF TTM 18.7m)
FCF Yield = 0.46% (FCF TTM 18.7m / Enterprise Value 4.02b)
FCF Margin = 1.22% (FCF TTM 18.7m / Revenue TTM 1.54b)
Net Margin = -22.90% (Net Income TTM -352.1m / Revenue TTM 1.54b)
Gross Margin = 17.57% ((Revenue TTM 1.54b - Cost of Revenue TTM 1.27b) / Revenue TTM)
Gross Margin QoQ = 16.29% (prev 18.33%)
Tobins Q-Ratio = 0.86 (Enterprise Value 4.02b / Total Assets 4.68b)
Interest Expense / Debt = 1.82% (Interest Expense 49.7m / Debt 2.72b)
Taxrate = 21.0% (US default 21%)
NOPAT = -141.4m (EBIT -179.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.59 (Total Current Assets 468.0m / Total Current Liabilities 30.0m)
Debt / Equity = 1.61 (Debt 2.72b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 25.59 (Net Debt 2.52b / EBITDA 98.6m)
Debt / FCF = 135.0 (Net Debt 2.52b / FCF TTM 18.7m)
Total Stockholder Equity = 1.86b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.06% (Net Income -352.1m / Total Assets 4.68b)
RoE = -18.90% (Net Income TTM -352.1m / Total Stockholder Equity 1.86b)
RoCE = -3.90% (EBIT -179.0m / Capital Employed (Equity 1.86b + L.T.Debt 2.72b))
RoIC = -3.05% (negative operating profit) (NOPAT -141.4m / Invested Capital 4.63b)
WACC = 4.06% (E(1.50b)/V(4.22b) * Re(8.82%) + D(2.72b)/V(4.22b) * Rd(1.82%) * (1-Tc(0.21)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.25%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈45.9m ; Y1≈30.2m ; Y5≈13.8m
Fair Price DCF = N/A (negative equity: EV 438.4m - Net Debt 2.52b = -2.08b; debt exceeds intrinsic value)
EPS Correlation: 39.48 | EPS CAGR: 44.45% | SUE: 1.28 | # QB: 1
Revenue Correlation: 94.06 | Revenue CAGR: 3.90% | SUE: 1.44 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.57 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+28.2% | Growth Revenue=+3.6%